Seonghyuk Park, Youngtaek Kim, Jihoon Ko, Jiyoung Song, Jeeyun Lee, Young-Kwon Hong, N. Jeon
{"title":"One-step achievement of tumor spheroid-induced angiogenesis in a high-throughput microfluidic platform: one-step tumor angiogenesis platform","authors":"Seonghyuk Park, Youngtaek Kim, Jihoon Ko, Jiyoung Song, Jeeyun Lee, Young-Kwon Hong, N. Jeon","doi":"10.51335/organoid.2023.3.e3","DOIUrl":null,"url":null,"abstract":"Research on the development of anti-cancer drugs has progressed, but the low reliability of animal experiments due to biological differences between animals and humans causes failures in the clinical process. To overcome this limitation, 3-dimensional (3D) in vitro models have been developed to mimic the human cellular microenvironment using polydimethylsiloxane (PDMS). However, due to the characteristics and limitations of PDMS, it has low efficiency and is not suitable to be applied in the preclinical testing of a drug. High-throughput microfluidic platforms fabricated by injection molding have been developed, but these platforms require a laborious process when handling spheroids. We recently developed an injection-molded plastic array 3D culture tissue platform that integrates the process from spheroid formation to reconstruction of an in vitro model with spheroids (All-in-One-IMPACT). In this study, we implemented a 3D tumor spheroid angiogenesis model in the developed platform. We analyzed the tendency for angiogenesis according to gel concentration and confirmed that angiogenesis occurred using cancer cell lines and patient-derived cancer cells (PDCs). We also administered an anti-cancer drug to the PDC tumor spheroid angiogenesis model to observe the drug’s effect on angiogenesis according to its concentration. We demonstrated that our platform can be used to study the tumor microenvironment (TME) and drug screening. We expect that this platform will contribute to further research on the complex mechanisms of the TME and predictive preclinical models.","PeriodicalId":100198,"journal":{"name":"Brain Organoid and Systems Neuroscience Journal","volume":"52 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain Organoid and Systems Neuroscience Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51335/organoid.2023.3.e3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Research on the development of anti-cancer drugs has progressed, but the low reliability of animal experiments due to biological differences between animals and humans causes failures in the clinical process. To overcome this limitation, 3-dimensional (3D) in vitro models have been developed to mimic the human cellular microenvironment using polydimethylsiloxane (PDMS). However, due to the characteristics and limitations of PDMS, it has low efficiency and is not suitable to be applied in the preclinical testing of a drug. High-throughput microfluidic platforms fabricated by injection molding have been developed, but these platforms require a laborious process when handling spheroids. We recently developed an injection-molded plastic array 3D culture tissue platform that integrates the process from spheroid formation to reconstruction of an in vitro model with spheroids (All-in-One-IMPACT). In this study, we implemented a 3D tumor spheroid angiogenesis model in the developed platform. We analyzed the tendency for angiogenesis according to gel concentration and confirmed that angiogenesis occurred using cancer cell lines and patient-derived cancer cells (PDCs). We also administered an anti-cancer drug to the PDC tumor spheroid angiogenesis model to observe the drug’s effect on angiogenesis according to its concentration. We demonstrated that our platform can be used to study the tumor microenvironment (TME) and drug screening. We expect that this platform will contribute to further research on the complex mechanisms of the TME and predictive preclinical models.
抗癌药物的开发研究取得了进展,但由于动物与人类的生物学差异,动物实验的可靠性较低,导致临床过程中的失败。为了克服这一限制,已经开发出三维(3D)体外模型,使用聚二甲基硅氧烷(PDMS)来模拟人类细胞微环境。然而,由于PDMS的特点和局限性,其效率较低,不适合应用于药物的临床前试验。高通量微流控平台已经开发出来,但这些平台在处理球体时需要一个费力的过程。我们最近开发了一种注射成型的塑料阵列3D培养组织平台,该平台集成了从球体形成到球体体外模型重建的过程(all -in- one impact)。在这项研究中,我们在开发的平台上实现了一个三维肿瘤球体血管生成模型。我们根据凝胶浓度分析了血管生成的趋势,并证实血管生成发生在癌细胞系和患者来源的癌细胞(PDCs)中。我们还将一种抗癌药物应用于PDC肿瘤球形血管生成模型,根据其浓度观察药物对血管生成的影响。我们证明了我们的平台可以用于研究肿瘤微环境(TME)和药物筛选。我们期望这个平台将有助于进一步研究TME的复杂机制和预测临床前模型。